4.2 Article

ABCC11/MRP8 polymorphisms affect 5-fluorouracil-induced severe toxicity and hepatic expression

期刊

PHARMACOGENOMICS
卷 14, 期 12, 页码 1433-1448

出版社

FUTURE MEDICINE LTD
DOI: 10.2217/pgs.13.139

关键词

5-fluorouracil; ABCC11; drug-metabolizing enzyme; drug transporter; haplotype; leukopenia; pharmacogenetics; pharmacogenomics; polymorphism; toxicity

资金

  1. German Federal Ministry of Education and Science (BMBF Virtual Liver Network) [0315755, 03 IS 2061C]
  2. 7FP EU Initial Training network program 'FightingDrugFailure' [GA-2009-238132]
  3. Robert-Bosch Foundation, Stuttgart, Germany

向作者/读者索取更多资源

Aim: Because 5-fluorodeoxyuridine monophosphate (5-FdUMP), an anabolic active metabolite of 5-fluorouracil (5-FU), is a substrate of MRP8 (encoded by ABCC11), we investigated whether ABCC11 polymorphisms play a role in severe toxicity of 5-FU. Patients & methods: Genomic DNA from 672 cancer patients treated with 5-FU monotherapy and with documented toxicity according to WHO criteria was genotyped for 12 ABCC11 tag SNPs. Functional impact of polymorphisms was assessed in a Caucasian human liver cohort (n = 150) and by recombinant expression of MRP8 protein variants. Results: Univariate and multivariate analysis identified rs17822471 (G>A, T546M) as risk factor of severe leukopenia (p = 0.021, odds ratio [95%CI]: 3.31 [1.26-8.66]) but not of other toxicity types. MRP8 protein expression in human liver was 1.7-fold lower in carriers compared with wild-type (p = 0.02). Recombinant expression confirmed the effect of T546M on protein expression. Conclusion: Since MRP8 is expressed in bone marrow blasts and leukocytes, lower expression may lead to intracellular accumulation of 5-FdUMP and increased risk of leukopenia. Original submitted 25 April 2013; Revision submitted 17 July 2013

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据